派林生物子公司获人凝血因子IX药品注册上市许可

Core Viewpoint - The company, Palin Bio (000403.SZ), announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received the acceptance notice for the drug registration and marketing license for human coagulation factor IX from the National Medical Products Administration [1] Group 1 - The approval signifies a significant milestone for the company in the biopharmaceutical sector [1] - The drug is expected to enhance the company's product portfolio and market presence in the coagulation factor segment [1] - This development may lead to potential revenue growth and increased investor interest in the company [1]